Same but different? A thematic analysis on adalimumab biosimilar switching among patients with juvenile idiopathic arthritis.

ABSTRACT:

Background

Biologic medications have dramatically enhanced the treatment of many chronic paediatric inflammatory conditions. Their high cost is a factor that prohibits their broader use. Cheaper generic versions, or biosimilars, are increasingly being used. Healthcare services are switching some patients over to biosimilars for economic reasons, known as 'non-medical switching'. Some patients unsuccessfully switch due to perceived decreases in efficacy or non-specific drug effects. The implications of failed switching include exhaustion of therapeutic options, unnecessary exposure to other medications, increased healthcare utilisation, worse patient outcomes and higher overall healthcare costs. Patient perceptions almost certainly play a role in these 'failed switches'.

Methods<

SUBMITTER: Renton WD 

PROVIDER: S-EPMC6778384 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature